Deutsche Bank AG raised its stake in Geron Co. (NASDAQ:GERN) by 155.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 887,681 shares of the biopharmaceutical company’s stock after buying an additional 539,621 shares during the period. Deutsche Bank AG’s holdings in Geron were worth $887,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. FMR LLC grew its position in shares of Geron by 158.4% in the fourth quarter. FMR LLC now owns 15,536,850 shares of the biopharmaceutical company’s stock valued at $15,537,000 after purchasing an additional 9,523,953 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Geron by 8.2% in the third quarter. Vanguard Group Inc. now owns 8,751,607 shares of the biopharmaceutical company’s stock valued at $15,403,000 after purchasing an additional 661,446 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Geron in the fourth quarter valued at approximately $188,000. SG Americas Securities LLC grew its position in shares of Geron by 99.6% in the fourth quarter. SG Americas Securities LLC now owns 56,479 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 28,181 shares during the last quarter. Finally, MetLife Investment Advisors LLC grew its position in shares of Geron by 50.1% in the third quarter. MetLife Investment Advisors LLC now owns 117,168 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 39,095 shares during the last quarter. Institutional investors and hedge funds own 31.99% of the company’s stock.

In related news, EVP Melissa Kelly Behrs sold 120,635 shares of the firm’s stock in a transaction that occurred on Tuesday, April 9th. The shares were sold at an average price of $2.00, for a total transaction of $241,270.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 8.20% of the stock is currently owned by company insiders.

Several research firms have recently commented on GERN. BidaskClub upgraded shares of Geron from a “hold” rating to a “buy” rating in a research report on Saturday, March 16th. BTIG Research began coverage on shares of Geron in a research report on Tuesday, February 12th. They issued a “buy” rating and a $4.00 price target on the stock. Needham & Company LLC upgraded shares of Geron from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Tuesday, April 9th. Finally, B. Riley upgraded shares of Geron from a “neutral” rating to a “buy” rating and increased their price target for the company from $1.50 to $3.25 in a research report on Thursday, January 31st. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Geron presently has an average rating of “Buy” and an average target price of $3.01.

GERN stock opened at $1.79 on Thursday. The company has a market capitalization of $309.62 million, a PE ratio of -11.19 and a beta of 2.93. Geron Co. has a 12 month low of $0.95 and a 12 month high of $6.99.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.02. Geron had a negative net margin of 3,713.04% and a negative return on equity of 17.53%. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.23 million. Sell-side analysts predict that Geron Co. will post -0.34 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://theolympiareport.com/2019/05/16/geron-co-gern-shares-bought-by-deutsche-bank-ag.html.

About Geron

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Read More: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. (NASDAQ:GERN).

Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.